CL2019002580A1 - Mythriboscines: Mitochondria-based therapeutic compounds that target cancer cells, bacteria, and pathogenic yeast. - Google Patents
Mythriboscines: Mitochondria-based therapeutic compounds that target cancer cells, bacteria, and pathogenic yeast.Info
- Publication number
- CL2019002580A1 CL2019002580A1 CL2019002580A CL2019002580A CL2019002580A1 CL 2019002580 A1 CL2019002580 A1 CL 2019002580A1 CL 2019002580 A CL2019002580 A CL 2019002580A CL 2019002580 A CL2019002580 A CL 2019002580A CL 2019002580 A1 CL2019002580 A1 CL 2019002580A1
- Authority
- CL
- Chile
- Prior art keywords
- mitochondria
- mitochondrial
- mythriboscines
- bacteria
- cancer cells
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 210000003470 mitochondria Anatomy 0.000 title abstract 2
- 230000001717 pathogenic effect Effects 0.000 title abstract 2
- 241000894006 Bacteria Species 0.000 title 1
- 210000004027 cell Anatomy 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 3
- 230000002438 mitochondrial effect Effects 0.000 abstract 3
- 230000003712 anti-aging effect Effects 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000004898 mitochondrial function Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
- C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/04—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/50—Molecular design, e.g. of drugs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Computing Systems (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
Abstract
LA PRESENTE DESCRIPCIÓN SE REFIERE A INHIBIDORES DE LA FUNCIÓN MITOCONDRIAL. SE DAN A CONOCER MÉTODOS DE PROSPECCIÓN DE LOS COMPUESTOS PARA LA INHIBICIÓN MITOCONDRIAL. TAMBIÉN SE DESCRIBEN MÉTODOS PARA USAR INHIBIDORES MITOCONDRIALES LLAMADOS MITORRIBOSCINAS - COMPUESTOS TERAPÉUTICOS BASADOS EN MITOCONDRIAS QUE TIENEN PROPIEDADES ANTI-CANCEROSAS Y ANTIBIÓTICAS - PARA PREVENIR O TRATAR EL CÁNCER, INFECCIONES BACTERIANAS Y LEVADURAS PATÓGENAS, ASÍ COMO TAMBIÉN MÉTODOS PARA USAR INHIBIDORES MITOCONDRIALES PARA PROPORCIONAR BENEFICIOS ANTI-ENVEJECIMIENTO. TAMBIÉN SE DAN A CONOCER COMPUESTOS ESPECÍFICOS DE MITORRIBOSCINA Y GRUPOS DE MITORRIBOSCINAS.THIS DESCRIPTION REFERS TO INHIBITORS OF MITOCHONDRIAL FUNCTION. PROSPECTING METHODS FOR MITOCHONDRIAL INHIBITION COMPOUNDS ARE DISCLOSED. ALSO DESCRIBED METHODS FOR USING INHIBITORS Mitochondrial CALLED MITORRIBOSCINAS - COMPOSITE based therapeutics Mitochondria have anti-cancerous and antibiotic - TO PREVENT OR TREAT CANCER, INFECTIONS BACTERIAL AND YEAST pathogenic WELL AS METHODS FOR USING INHIBITORS Mitochondrial TO PROVIDE BENEFITS ANTI -AGING. SPECIFIC MITORRIBOSCINE COMPOUNDS AND MITORRIBOSCINE GROUPS ARE ALSO LEARNED.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762471688P | 2017-03-15 | 2017-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2019002580A1 true CL2019002580A1 (en) | 2020-02-14 |
Family
ID=63523316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019002580A CL2019002580A1 (en) | 2017-03-15 | 2019-09-10 | Mythriboscines: Mitochondria-based therapeutic compounds that target cancer cells, bacteria, and pathogenic yeast. |
Country Status (23)
Country | Link |
---|---|
US (4) | US11311501B2 (en) |
EP (1) | EP3596043A1 (en) |
JP (2) | JP7104134B2 (en) |
KR (1) | KR102623283B1 (en) |
CN (1) | CN110621655B (en) |
AU (2) | AU2018235937A1 (en) |
BR (1) | BR112019019109B1 (en) |
CA (1) | CA3056086A1 (en) |
CL (1) | CL2019002580A1 (en) |
CO (1) | CO2019010027A2 (en) |
CR (2) | CR20190458A (en) |
CU (3) | CU20190079A7 (en) |
DO (3) | DOP2019000230A (en) |
EC (1) | ECSP19073204A (en) |
IL (2) | IL305316B1 (en) |
MX (3) | MX2019010759A (en) |
NZ (1) | NZ756854A (en) |
PE (1) | PE20191485A1 (en) |
PH (1) | PH12019502056A1 (en) |
RU (1) | RU2019132396A (en) |
SG (1) | SG11201908487YA (en) |
WO (1) | WO2018170109A1 (en) |
ZA (5) | ZA201905970B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019075209A1 (en) | 2017-10-11 | 2019-04-18 | Lunella Biotech, Inc. | Anti-mitochondrial inhibitors for oncogenic ras and myc |
EP3860616A4 (en) | 2018-10-02 | 2022-07-06 | Lunella Biotech, Inc. | Azithromycin and roxithromycin derivatives as senolytic drugs |
CA3123850A1 (en) | 2018-12-17 | 2020-06-25 | Lunella Biotech, Inc. | Triple combination therapies for anti-aging |
CA3123838A1 (en) * | 2018-12-17 | 2020-06-25 | Lunella Biotech, Inc. | Triple combination therapies for targeting mitochondria and killing cancer stem cells |
CN114025769A (en) * | 2019-04-16 | 2022-02-08 | 卢内拉生物技术有限公司 | alkyl-TPP compounds for targeted mitochondrial and anticancer therapy |
WO2020242857A1 (en) * | 2019-05-24 | 2020-12-03 | Lunella Biotech, Inc. | Therapeutics and methods for predicting and overcoming endocrine resistance in breast cancer |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2062025A (en) * | 1931-12-19 | 1936-11-24 | Harrington Joseph | Method and apparatus for treating moisture-containing substances |
US2059764A (en) * | 1933-11-03 | 1936-11-03 | Zerillo Frank | Pneumatic tire |
US2058655A (en) * | 1934-10-12 | 1936-10-27 | Borg Warner | Friction clutch |
JPS537424B2 (en) | 1971-10-08 | 1978-03-17 | ||
US5756507A (en) * | 1995-12-14 | 1998-05-26 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
JP2000001433A (en) | 1998-06-11 | 2000-01-07 | Pfizer Pharmaceuticals Inc | 5-lipoxygenase inhibitor |
GB0323585D0 (en) * | 2003-10-08 | 2003-11-12 | Glaxo Group Ltd | Compounds |
EA200901236A1 (en) | 2004-03-16 | 2009-12-30 | Темпл Юниверсити - Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн | SUBSTITUTED PHENOXY AND PHENYL DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISTURBANCES |
CA2588285A1 (en) * | 2004-11-29 | 2006-06-01 | National University Corporation Nagoya University | Glycopeptide antibiotic monomer derivatives |
RU2008145871A (en) * | 2006-04-21 | 2010-05-27 | Смитклайн Бичам Корпорейшн (US) | IL-8 RECEPTOR ANTAGONISTS |
PE20081882A1 (en) * | 2007-03-15 | 2008-12-27 | Schering Corp | USEFUL PYRIDAZINONE DERIVATIVES AS GLUCAN SYNTHASE INHIBITORS |
FR2932483A1 (en) | 2008-06-13 | 2009-12-18 | Cytomics Systems | COMPOUNDS USEFUL FOR THE TREATMENT OF CANCERS. |
DK2391363T3 (en) * | 2009-01-29 | 2017-01-16 | Young Hee Ko | COMPOSITIONS AND PROCEDURES FOR TREATING CANCER |
EP2433133A2 (en) * | 2009-05-20 | 2012-03-28 | Universite De Geneve | Mitochondrial activity inhibitors of cancer-initiating cells and use thereof |
JP5889895B2 (en) * | 2010-07-29 | 2016-03-22 | ライジェル ファーマシューティカルズ, インコーポレイテッド | AMPK activated heterocyclic compounds and methods of use thereof |
WO2013006734A1 (en) | 2011-07-05 | 2013-01-10 | St. Jude Children's Research Hospital | Substituted 4-phenoxyphenol analogs as modulators of proliferating cell nuclear antigen activity |
CN102886054B (en) * | 2011-07-19 | 2014-04-02 | 复旦大学 | Preparation for inhibiting activity of PhoQ histidine kinase of bacterial signal transduction system |
DK2950649T3 (en) * | 2013-02-01 | 2020-05-04 | Wellstat Therapeutics Corp | AMINE COMPOUNDS WITH ANTI-INFLAMMATION, ANTI-FUNGI, ANTIPARASITY AND ANTICANCER ACTIVITY |
CA2884607A1 (en) * | 2015-03-11 | 2016-09-11 | Stealth Peptides International, Inc. | Therapeutic compositions including acrylamido compounds or phenyl-substiituted maleimide compounds and uses thereof to treat and prevent mitochondrial diseases and conditions |
-
2018
- 2018-03-14 IL IL305316A patent/IL305316B1/en unknown
- 2018-03-14 CU CU2019000079A patent/CU20190079A7/en unknown
- 2018-03-14 CR CR20190458A patent/CR20190458A/en unknown
- 2018-03-14 NZ NZ756854A patent/NZ756854A/en unknown
- 2018-03-14 CA CA3056086A patent/CA3056086A1/en active Pending
- 2018-03-14 MX MX2019010759A patent/MX2019010759A/en unknown
- 2018-03-14 SG SG11201908487Y patent/SG11201908487YA/en unknown
- 2018-03-14 CU CU2019000096A patent/CU20190096A7/en unknown
- 2018-03-14 KR KR1020197029542A patent/KR102623283B1/en active IP Right Grant
- 2018-03-14 JP JP2020500006A patent/JP7104134B2/en active Active
- 2018-03-14 PE PE2019001841A patent/PE20191485A1/en unknown
- 2018-03-14 BR BR112019019109-7A patent/BR112019019109B1/en active IP Right Grant
- 2018-03-14 WO PCT/US2018/022403 patent/WO2018170109A1/en active Application Filing
- 2018-03-14 EP EP18767458.5A patent/EP3596043A1/en active Pending
- 2018-03-14 RU RU2019132396A patent/RU2019132396A/en unknown
- 2018-03-14 US US16/493,871 patent/US11311501B2/en active Active
- 2018-03-14 CN CN201880031954.5A patent/CN110621655B/en active Active
- 2018-03-14 CU CU2019000097A patent/CU20190097A7/en unknown
- 2018-03-14 AU AU2018235937A patent/AU2018235937A1/en not_active Abandoned
- 2018-03-14 IL IL269309A patent/IL269309B2/en unknown
- 2018-03-14 MX MX2022000938A patent/MX2022000938A/en unknown
- 2018-03-14 CR CR20220381A patent/CR20220381A/en unknown
- 2018-03-14 MX MX2022000937A patent/MX2022000937A/en unknown
- 2018-11-29 US US16/204,173 patent/US10512618B2/en active Active
-
2019
- 2019-09-06 DO DO2019000230A patent/DOP2019000230A/en unknown
- 2019-09-10 CL CL2019002580A patent/CL2019002580A1/en unknown
- 2019-09-10 ZA ZA2019/05970A patent/ZA201905970B/en unknown
- 2019-09-10 PH PH12019502056A patent/PH12019502056A1/en unknown
- 2019-09-16 CO CONC2019/0010027A patent/CO2019010027A2/en unknown
- 2019-10-10 EC ECSENADI201973204A patent/ECSP19073204A/en unknown
- 2019-10-31 US US16/670,326 patent/US11547679B2/en active Active
- 2019-10-31 US US16/670,443 patent/US11364210B2/en active Active
-
2020
- 2020-02-19 ZA ZA2020/01040A patent/ZA202001040B/en unknown
- 2020-02-19 ZA ZA2020/01041A patent/ZA202001041B/en unknown
-
2021
- 2021-03-05 ZA ZA2021/01517A patent/ZA202101517B/en unknown
-
2022
- 2022-03-29 ZA ZA2022/03603A patent/ZA202203603B/en unknown
- 2022-07-07 JP JP2022109390A patent/JP7312891B2/en active Active
- 2022-07-13 AU AU2022205218A patent/AU2022205218B2/en active Active
- 2022-08-11 DO DO2022000165A patent/DOP2022000165A/en unknown
- 2022-08-11 DO DO2022000164A patent/DOP2022000164A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019002580A1 (en) | Mythriboscines: Mitochondria-based therapeutic compounds that target cancer cells, bacteria, and pathogenic yeast. | |
CO2018009275A2 (en) | Spiro-condensed pyrrolidine derivatives as inhibitors of desubiquitinating enzymes (dub) | |
CL2020000169A1 (en) | Macrocyclic compounds and their uses. | |
BR112017024384A2 (en) | bacteria modified to reduce hyperphenylalaninemia | |
UY36748A (en) | AMINOPIRIDINE COMPOUNDS REPLACED WITH HETEROARILO AS QUINASE INHIBITORS AND IRAK-4 MODULATORS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
BR112018006811A2 (en) | therapeutic compounds and methods | |
NI201600056A (en) | BROMODOMINIUM INHIBITORS | |
AR102657A1 (en) | COMPOSITION TO TREAT FABRICS | |
UY36747A (en) | AMINOPIRIDINE COMPOUNDS REPLACED WITH HETEROARILO AS QUINASE INHIBITORS AND MODULANTS OF IRAK-4 AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
UY36749A (en) | AMINOPIRIDINE COMPOUNDS REPLACED WITH HETEROARILO AS QUINASE INHIBITORS AND IRAK-4 MODULATORS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
CO2017005870A2 (en) | Hydroxamic acid isoxazole compounds as lpxc inhibitors | |
DOP2019000019A (en) | METHODS TO TREAT PROSTATE CANCER | |
CL2019003708A1 (en) | Mitoketoskines: Mitochondria-based therapeutic agents that target ketone metabolism in cancer cells. | |
ECSP20027220A (en) | MITOFLAVOSCINS: TARGETING BINDING OF ENZYMES CONTAINING FLAVIN KILLS CANCER STEM CELLS (CSCS) BY INHIBITING MITOCHONDRIAL RESPIRATION | |
UY35274A (en) | COMPOUNDS AND METHODS TO TREAT BACTERIAL INFECTIONS | |
CR20160474A (en) | SYSTEM AND METHOD FOR WATER TREATMENT SYSTEMS WITH HIGH VOLTAGE AND OZONE DISCHARGE | |
BR112018069927A2 (en) | cancer therapy with an oncolytic virus combined with a checkpoint inhibitor | |
CY1122403T1 (en) | DOSAGE FORMS AND THERAPEUTIC USES OF L-4-CHLOROKYNURENINE | |
BR112017011642A2 (en) | compound, pharmaceutically acceptable salt, and method for treating a disease or condition that benefits from an increase in nad +. | |
WO2015196121A3 (en) | Method of treating ovarian cancer using a pkc inhibitor | |
UY39779A (en) | MACROCYCLIC COMPOUNDS TO TREAT DISEASES | |
BR112017021114A2 (en) | heterocyclic compounds as lsd1 inhibitors |